logo
What are today's HELOC and home equity loan interest rates?

What are today's HELOC and home equity loan interest rates?

CBS News5 days ago
In the elevated interest rate climate of recent years, there have been few affordable borrowing options to choose from. Personal loan interest rates, for example, have been frozen at around 12% for months while credit card interest rates have declined recently, but only from a recent record high of 23%. Double-digit rates for both make borrowing with either especially cost-prohibitive right now, even with the potential for interest rate cuts to be issued later in 2025.
One smart and effective way to borrow, however, is readily available for homeowners right now via their home equity. With the average equity level comfortably sitting over $300,000 currently, borrowing with a home equity loan or home equity line of credit (HELOC) makes sense. And with rates here significantly lower than most alternatives, and with those rates poised to drop alongside a declining federal funds rate in the months ahead, either could be the ideal way to borrow a large sum of money at an affordable cost.
Before getting started, homeowners should first familiarize themselves with today's average HELOC and home equity loan rates, both of which change often based on market conditions.
Start the process by seeing how much home equity you could borrow here now.
As of July 30, 2025, here's what the average home equity loan interest rates are, according to Bankrate:
The average HELOC rate is now 8.26%, according to Bankrate. However, all of these rates are nationwide averages, and the offers you may receive will be impacted by location, lender, credit profile, and more. Take the time, then, to shop around to find the lowest rates and best terms.
Start shopping for HELOCs and home equity loans online today.
HELOCs and home equity loans both use your equity as the funding source, but the way they operate differs. Home equity loans come with fixed interest rates and provide the homeowner with a lump sum of money of which repayments will be expected to be made immediately.
HELOCs, on the other hand, come with variable interest rates and provide the homeowner with a revolving line of credit using the home as the funding source. Payments will only need to be made on the amount of credit used, not the full line of credit you've been approved for. And, for an initial draw period, interest-only payments will be required before the repayment period kicks in (typically after 10 or 15 years).
In addition to lower interest rates when compared to alternative borrowing products, both HELOCs and home equity loans have some attractive tax benefits. If the owner uses either product for IRS-eligible home repairs and renovations, they may be able to deduct the interest they paid from their taxes for the year or years in which the product was used. Still, with the home functioning as collateral and the possibility of it being foreclosed on if payments aren't made as agreed to, it's critical for homeowners to choose the right product for their needs and budget.
HELOC and home equity loan rates are lower than many alternative borrowing products right now, and they're poised to decline further if the Federal Reserve cuts rates again later this year. Still, not every lender will offer the same rates and terms, and with your home as collateral, it's critical to shop around to find the right product for your budget and financial goals.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory

Yahoo

time14 minutes ago

  • Yahoo

Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on Valueinvesting subreddit by bluespacecolombo. In this article, we will summarize the bulls' thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at $27.61 as of July 28th. A scientist in a laboratory coat looking into a microscope at human bone regeneration samples. Ultragenyx Pharmaceutical (RARE) has seen its share price halve in just two weeks, largely due to a halted trial and an FDA rejection, but the market appears to have overreacted. The company's Phase 3 trial for setrusumab, a potential blockbuster therapy for a rare bone disease, failed to meet an early 'stop-for-efficacy' milestone, yet the study remains on track, with safety intact and final results expected in late 2025 under less stringent endpoints. Meanwhile, the FDA issued a complete response letter for another gene therapy candidate, citing manufacturing issues rather than safety or efficacy concerns. The program remains viable, with a resubmission expected once production adjustments are made. Despite these setbacks, Ultragenyx continues to generate meaningful revenue, posting $139 million in Q1 and guiding for over $640 million in 2025, and maintains a robust cash position of around $560 million, with management projecting lower cash burn. Beyond setrusumab, the company's pipeline is well diversified, featuring DTX401, a gene therapy for glycogen storage disease that met Phase 3 goals and is slated for FDA submission this year, as well as an advanced Angelman syndrome program in Phase 3. None of the recent regulatory or clinical updates involved failures of safety or efficacy, leaving the scientific foundation of the pipeline intact. Analysts' average price targets remain near $100, implying a potential threefold upside from the current ~$26 level. With solid fundamentals, multiple near-term catalysts, and a temporarily depressed valuation, Ultragenyx represents a compelling contrarian opportunity as panic-driven selling unwinds. Previously we covered a bullish thesis on Capricor Therapeutics, Inc. (CAPR) by androidmj in March 2025, which highlighted the upcoming FDA decision on Deramiocel, strong financial backing, and significant upside on approval. The company's stock has depreciated about 46.32% since then as the thesis has yet to play out. The thesis still stands given CAPR's cash runway and de-risked catalyst. bluespacecolombo shares a similar view on the biotech space but emphasizes Ultragenyx's diversified pipeline, overreaction-driven selloff, and near-term catalysts. Ultragenyx Pharmaceutical Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 55 hedge fund portfolios held RARE at the end of the first quarter which was 57 in the previous quarter. While we acknowledge the potential of RARE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Tesla Offers Musk $30 Billion to Stay--With Strings Attached
Tesla Offers Musk $30 Billion to Stay--With Strings Attached

Yahoo

time14 minutes ago

  • Yahoo

Tesla Offers Musk $30 Billion to Stay--With Strings Attached

Tesla (NASDAQ:TSLA) just handed CEO Elon Musk a massive new stock awardworth around $30 billiondesigned to keep him anchored at the helm while the company weathers legal battles and business headwinds. The package includes 96 million shares at a $23.34 exercise price, and it only kicks in if Musk stays in a senior leadership role for another two years. It's a stopgap move while the board appeals a court decision that voided his original 2018 compensation plan. That plan, once pegged at $56 billion, has become a flashpoint for investors and governance advocates alike. The interim award signals Tesla's intent to keep Musk focused during a volatile phase for the business. Tesla's board calls this a good faith gestureand timing matters. After a tough first half marked by declining sales, falling revenue, and a 25% YTD drop in share price, the company is leaning heavily on Musk's leadership to navigate what it describes as a critical inflection point. According to Wedbush analyst Dan Ives, the new agreement helps remove a lingering cloud over the stock and likely cements Musk's role for the foreseeable future. The board is also developing a longer-term pay structure, to be voted on at the November 6 shareholder meeting. But leadership retention isn't the only thing on the line. Musk's attention has been split across multiple venturesSpaceX, xAI, X Corp, Neuralink, The Boring Companyand his recent political entanglements haven't helped. The board acknowledges these distractions but says Musk remains central to Tesla's ability to attract and retain talent. Meanwhile, Tesla is trying to build momentum around its new robotaxi program, launched in Austin, which could be a long-term growth lever. Whether this compensation reset keeps Musk focused on Teslaor just buys timeis what investors will be watching next. This article first appeared on GuruFocus. Sign in to access your portfolio

How to get free Burger King Whoppers for 6 days straight
How to get free Burger King Whoppers for 6 days straight

Yahoo

time14 minutes ago

  • Yahoo

How to get free Burger King Whoppers for 6 days straight

Burger King and Walmart+ lovers to the front. The companies are offering a deal that'll give customers a free Whopper with a $1 purchase for six days straight. The deal is only available for shoppers who are members of both Walmart+ and Burger King Royal Perks programs, a Burger King representative told USA TODAY via email. The deal will run from Tuesday, Aug. 5, to Monday, Aug. 11. The special was announced to celebrate the one-year anniversary of Walmart and Burger King's first-ever joint promotion, launched last summer. Last year's deal gave Walmart+ members 25% off any Burger King digital order every day, as well as a free Whopper every three months starting in September 2024. Here's what to know to get the deal: Read more: Walmart+ members get 25% off Burger King, free Whoppers in new partnership How can I get my free Whopper this week? Guests can take advantage of the deal by linking their Burger King Royal Perks and Walmart+ accounts. To link your accounts: Make sure the Burger King app is downloaded on your device. Download the Walmart app and sign in. Or, log in at Go to "Account." Select "Walmart+ membership." Find the Burger King Savings benefit and select "Get started." The Burger King app should open automatically. Select the "Link accounts" button. Once customers have linked their Walmart+ and Burger King accounts, they can redeem the offer by: ordering in-store using their 6-digit code, opening the Burger King app, going to the 'Offers' tab and activating the offer, and logging in at to place an order. Did someone say diner? Elon Musk fans flock to new Tesla Diner Are there any restrictions? The deal is not available during breakfast hours except at select locations, and customers can only get one free Whopper per account each day, Burger King said. The offer cannot be used with delivery orders. More on Walmart+ and Burger King Royal Perks Walmart+ is Walmart's delivery program that starts at $12.95 a month or $98 annually. The program has student and government assistance eligibility, per the company's website. Royal Parks is Burger King's free rewards program that allows customers to earn points, or crowns, for every $1 spent on eligible transactions. Customers can then cash in the crowns for free menu items. Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@ This article originally appeared on USA TODAY: Got Walmart+ and Burger King Royal Perks? Get a free Whopper.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store